Made-in-Canada Medly® for Heart Failure to Relieve Hospital Overload

TORONTO, Canada — February 25, 2026 — VITALL Intelligence Inc. (VITALL), today announced the commercial availability of Medly®, a clinically validated digital therapeutic for heart failure developed at University Health Network (UHN). As UHN’s exclusive, global licensee VITALL will deliver the Medly service from its digital health platform enabling cardiac centres to equip heart failure patients with the service.

Heart failure is a leading cause of hospital admissions and readmissions in Canada, with an average length of stay of 9.6 days according to CIHI[1]. Medly is an evidence-based digital therapeutic whose use by more than 3,000 patients through UHN, UHN collaborators, and two Indigenous Health Authorities has demonstrated:

• 50% reduction in heart failure related hospitalizations
• 35% fewer in-person appointments
• Faster optimization of guideline directed medical therapy (GDMT)

Clinical results are supported by more than 30 peer reviewed publications with key findings summarized in a white paper available at https://www.vitall.com/medly-white-paper.

A Rare Demand-Side Lever for Health Systems Under Strain

Emergency departments and in-patient units across Canada are under sustained pressure from rising demand for specialized care. While hospital staff work tirelessly to optimize the supply of services — beds, staff, and clinic capacity — few tools exist to meaningfully reduce demand. The health system needs proven, scalable levers that can reduce avoidable emergency visits, shorten lengths of stay, and lessen in-person clinic visits.

Medly— an AI-enhanced, Health Canada–approved digital therapeutic installed on a heart failure patient’s smartphone – enables daily, iterative proposed adjustments to their medication and care at home, and is associated with fewer decompensating events that can lead to emergency visits and lengthy hospital stays.

“Canadian health systems must adopt high impact programs that help rebalance the growing demand for specialized care with the limited supply of hospital resources,” said Don Simmonds, Chairman and CEO of VITALL. “Medly provides a responsible, proven technology solution that improves patient outcomes while freeing beds, reducing emergency visits, and easing the burden on clinical teams — all through a single program.”

How Medly Works in Practice

Medly extends the reach of cardiac care teams through a smartphone-based therapeutic that, with physician oversight, guides daily medication and care adjustments. Key patient health metrics are captured at home, and Medly’s expert system provides tailored guidance while flagging changes in status to clinicians through a real-time dashboard. Nurse-led teams, supported by cardiologists, can intervene earlier, helping patients avoid preventable deterioration and unnecessary hospital visits.  

Patients who have used Medly report improved symptom control, reduced anxiety, and greater confidence in managing their own care.  Clinicians using Medly benefit from predictable workflows, fewer routine visits, and increased capacity to focus on patients with the greatest needs.

System Level Impact: Relief Where It Matters Most

A subset of heart failure patients — roughly 20% within Class III and IV categories of the New York Heart Failure Classification System[2] — account for the majority of heart failure re-hospitalizations and require highly specialized, resource-intensive care. On average, patients in this cohort are hospitalized 1.5 times each year at a cost of care that can exceed $1,800 per day imposing a burden on our health systems of some $27,000 per patient each year.

By reducing avoidable hospitalizations and emergency department visits, VITALL believes Medly has the ability to:

• Free beds and shorten wait times
• Reduce staff burnout and turnover
• Expand access to care, including in rural and indigenous communities
• Enable nurses to work remotely while maintaining high quality oversight

Medly can also assist in achieving faster guideline directed medical therapy (GDMT) optimization, which can lead to improved patient outcomes and potential extended life spans[3].

A Turnkey Service for Hospitals and Health Systems

VITALL offers Medly as an all-inclusive service for hospitals and regional health authorities, including implementation, workflow integration, clinician training, and ongoing operational support. The service is designed for rapid scale across hospital networks and regional systems with minimal disruption to existing clinical operations.

About VITALL-Medly

VITALL’s platform consolidates clinical data, medical device inputs, and at home tests into a unified, real-time view of a patient’s health journey. Built on a SOC II–certified FHIR architecture with strong patient consent controls, VITALL delivers secure, accessible, and actionable health information to patients and their circle of care. As a licensee of University Health Network (UHN), VITALL is the exclusive, global provider of Medly for heart failure.

For further information, contact:   Kirk Fergusson - kfergusson@vitall.com

‍

‍

[1] According to the Canadian Institute for Health Information (CIHI) the most common reason for hospitalization in 2023–2024 was giving birth, with an average acute Length of Stay (LOS) of 2.1 days. This was followed by chronic obstructive pulmonary disease (COPD) and bronchitis (7.1 days) and heart failure (9.6 days).

[2] The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Little, Brown & Co.; 1994.

[3] In a comparative modelling analysis of three randomized trials, Vaduganathan et al. projected that in chronic HFrEF, implementation of comprehensive disease-modifying pharmacological therapy (ARNI, β-blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (ACEi/ARB plus β-blocker) was associated with gains in estimated residual lifespan of 6.3 years at age 55, 4.4 years at age 65, and 1.4 years at age 80.

‍